Market Overview
According to the latest research report published by DataM Intelligence, the Global Animal Vaccine Market was valued at US$ 12,089.2 million in 2022 and is projected to reach US$ 22,404.3 million by 2030. The market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).
The global animal vaccine market is segmented on the basis of product type, animal type, route of administration, and region. North America is expected to contribute significantly to the market growth due to manufacturers in North America may expand their operations as the need for animal vaccines for therapeutic purposes in healthcare grows. Major players in the market include Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Services LLC, Ceva, Vetoquinol, Elanco, Veterquimica S.A., Phibro Animal Health Corporation, KBNP, Inc. and Kyoto Biken Laboratories, Inc. among others.
The global popularity of ruminant vaccinations, particularly cow vaccines, is driven by growing outbreaks of bovine illness and an ever-increasing livestock population. Animals are an important source of meat, protein, food, milk, and other commercial items like wool and leather. The most often used animal vaccinations include rabies, equine influenza, and foot and mouth disease vaccines, which reduce infectious agent transmission by replicating naturally acquired immunity.
The global animal vaccine market trends reflect increased regulatory approvals for vaccines due to the growing occurrence of animal infectious illnesses and increased research and development.
Furthermore, the many clinical studies, together with an increased need for infection prevention at the point of care, are driving up the size of the animal vaccine market. The market is experiencing a surge in demand from North American areas as research in these fields expands. The competitive battle is increasing the animal vaccine market expansion, with important rivals such as Ceva, Elanco, Zoetis Services LLC, and others actively functioning in the industry.
For More Insights about the Market Request free Sample: https://www.datamintelligence.com/download-sample/animal-vaccine-market
Market Drivers
The animal vaccines market will most likely be driven by expanding development in companion or aquaculture vaccine manufacturing across the globe during the forecasting period. Farm-raised fish may be protected by inexpensive, efficient plant-based vaccines.
Vaccination is a rapid, efficient, and preventive means of keeping fish healthy. Vaccines stimulate an animal’s immune system to develop a protective response. Vaccinations strengthen the animal’s immune system and raise its ability to withstand sickness when viruses are met naturally. Vaccines include antigens from harmful organisms that have undergone numerous procedures to become non-pathogenic.
Numerous preclinical and clinical studies have shown that manufacturing plant vaccines are viable, productive, and safe. For recombinant subunit vaccines, using a plant-based platform may be useful. Unlike live vaccines, plant-based immunizations do not pose the same safety concerns.
In contrast to mammalian-based systems, undesirable or harmful components such as bacterial toxins and unwanted yeast proteins were not discovered in plant-based manufacturing processes. The increased innovation in animal vaccine manufacturing is a major driver driving the global animal vaccines market’s rise.
Market Opportunities
Rising Government Initiatives and Novel Product Launches Provide Manufacturers With Lucrative Opportunities.
There is significant market potential for animal vaccines because of escalating innovations, regulatory approvals, and the increasing occurrence of infectious illnesses. The increasing number of innovative product releases by major key players is also a global trend boosting the animal vaccination market.
Shri Narendra Singh Tomar, the Union Minister of Agriculture and Farmers’ Welfare, launched animal vaccination and other diagnostic kits developed by the ICAR-National Research Centre on Equines in June 2022.
The Ancovax vaccination for Equines is an inactivated (COVID-19) SARS-CoV-2 Delta vaccination for animals. Ancovax-induced immunity neutralizes both the Delta and Omicron variants of SARS-CoV-2. Alhydrogel is used in the vaccine as an adjuvant, as is inactivated SARS-CoV-2 (Delta) antigen. It is safe for dogs, lions, leopards, mice, and rabbits.
Market Restraints
The Complexity of Vaccine Production Will Hamper Market Growth.
It is a challenging effort to create vaccinations. Even the most basic steps may be difficult to follow to generate a dependable, consistent, and safe vaccine. Complex processes must be created at a high cost. The variety in raw materials, the disease-causing agent, environmental conditions, manufacturing competency, and the core production techniques all add to the complexity.
Many of the tests used to verify each step have high inherent variability. Failure to manage these risks may result in vaccination failure and costly vaccine recalls. Several pathogens must be created, including viruses and bacteria, to make live attenuated and inactivated vaccines. Consequently, there is a significant time lag between the start of manufacturing and the vaccine delivery.
Growth Factors
Rising food security concerns and growing animal husbandry increase the demand for livestock immunizations. Global livestock output has expanded as the need for animal products has increased. Furthermore, a range of factors, such as changing dietary preferences and population growth, are increasing the demand for cow products. These factors are aiding the market’s growth.
Moreover, the continual development of technologically advanced vaccinations and the outbreak of cattle illnesses have caused market dynamics to evolve.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war is expected to have a mild influence on the global animal vaccination market because of the low incidence and lack of important market competitors in this area. However, raw material imports and exports are predicted to have a minimal impact on the global animal vaccine market growth throughout the forecast period.
Recent Industry Developments
- In September 2022, Merck Animal Health, a division of Merck & Co., Inc., established a formal agreement under which Merck Animal Health would buy Vence from its founders and investors. Merck Animal Health is known as MSD Animal Health in countries other than the United States and Canada. Vence is a pioneer in virtual fencing for livestock management and rotational grazing.
- Ceva Santé Animale (Ceva) bought Artemis Technologies, a Canadian manufacturer of the oral rabies vaccine, in May 2022. Artemis in Guelph, Canada, developed an oral rabies glycoprotein recombinant vaccine called ONRAB, authorized for use on striped skunks (Mephitis mephitis) in that nation. The chemical was tested on wild skunks and raccoons in the United States.
- According to a statement from Zoetis Inc., the U.S. Food and Drug Administration (FDA) approved Solensia in January 2022 to assist cats with osteoarthritis (OA) in managing their pain and boost their comfort, mobility, and overall well-being. Solensia, a once-monthly injectable administered at the veterinary clinic, keeps OA pain from interfering with cats’ particular bond with their human partners.
Segmentation Analysis
As per the research analysis, the global animal vaccine market is segmented by product type into modified-live (attenuated) vaccine, inactivated (killed) vaccine, recombinant vaccine, and toxoid vaccine; by animal type into companion animal, livestock animal, aquaculture; and by route of administration into subcutaneous, intramuscular, and intranasal.
The Companion Animal Segment Accounted for around 37.5% of the Animal Vaccine Market Share due to Adoption
The fast-expanding adoption of companion animals all over the globe is one of the driving factors in the sector of animal vaccines market. Vaccination is the cornerstone of protecting pets against many diseases, most difficult or impossible to cure. Despite the risks they regularly face from the environment, travel, and both direct and indirect contact with ill or unvaccinated animals, dogs benefit from disease prevention.
Every pet has different risk factors. Therefore, it’s important to discuss them with the veterinarian so that the right vaccines are provided. Each UK-authorized vaccination’s Summary of Product Characteristics (SPC) offers information on the numerous vaccines accessible to the general public. The American Animal Hospital Association (AAHA) divides companion animal vaccinations into core and non-core.
Although non-core vaccinations are administered based on risk factors (such as geographic location and pet lifestyle), core immunizations are recommended for all cats and dogs. Because the first protection provided by mother’s milk is only effective for a few weeks, the first set of dog immunizations should be administered between the ages of 6 and 8 weeks. The companion animal industry has substantial prospects for the animal vaccinations business to broaden its reach and client base.
View Full Report: https://www.datamintelligence.com/research-report/animal-vaccine-market
Geographical Share
The global animal vaccine market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Animal Vaccine Market
Manufacturers in North America may expand their operations as the need for animal vaccines for therapeutic purposes in healthcare grows. North America has numerous manufacturers and suppliers, and due to the region’s rapid economic expansion, industrial output has risen, fueling demand for animal vaccination.
Increasing healthcare spending and public awareness, the progress of treatment technologies, and a rise in biopharmaceutical establishments throughout the area are all contributing to the region’s animal vaccination market share growth.
The collaborative research efforts of primary healthcare organizations and enterprises and new product development that constantly tries to improve treatment alternatives are also projected to contribute to increased demand. Individuals are becoming more aware of the different innovative procedures being researched for vaccine manufacturing, causing the market in this sector to expand.
Market Key players
The major companies contributing to the global animal vaccine market growth include Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Services LLC, Ceva, Vetoquinol, Elanco, Veterquimica S.A., Phibro Animal Health Corporation, KBNP, Inc. and Kyoto Biken Laboratories, Inc. among others.
Related Reports:
- Global Anti-rabies Vaccine Market
- Global Aquaculture Vaccines Market
- Global Companion Animal Health Market
- Global Animal Biotechnology Market
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query regarding the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights.
- The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021) and verifiable market size projections (2022-2029).
- Visualize the composition of the global animal vaccine market segmentation product type, animal type, route of administration, and region, highlighting the key commercial assets and players.
- By Product Type: Modified-live (attenuated) vaccine, inactivated (killed) vaccine, recombinant vaccine, and toxoid vaccine
- By Animal Type: Companion animal, livestock animal, aquaculture
- By Route of Administration: Subcutaneous, intramuscular, and intranasal.
- By Region: North America, Europe, South America, Asia-Pacific, and Middle East and Africa.
- Identify commercial opportunities in the global animal vaccine market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter’s five forces, regulations in each country, reimbursement scenario, technological advancements, PEST analysis and pricing analysis.
- Excel data sheet with thousands of the global animal vaccine market-level 4/5 segmentation data points.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players.
The report will provide access to approximately 50+ market data tables, 40+ figures and close to 180 pages.
About DataM Intelligence:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.